Dr. Madhav Danthala

Education Qualifications

• 2019-2020: Fellowship in Leukemia and Bone Marrow Transplantation, Vancouver General Hospital, University of British Columbia, Canada
• 2018-2019: Operational Research Certificate Course, WHO, SORT IT, The Union
• 2014-2017: DM (Medical Oncology), Nizam’s Institute of Medical Sciences, Hyderabad
• 2010-2013: MD (Internal Medicine), Sri Devaraj Urs Medical College, Kolar, Karnataka
• 2003-2009: MBBS, PES Institute of Medical Sciences and Research, Kuppam, Andhra Pradesh 

Experience

• Feb 2022-Present: Consultant Hemato-Oncologist and Bone Marrow Transplant Physician, Yashoda Hospitals, Somajiguda
• July 2019-Aug 2020: Clinical Fellow Leukemia and Bone Marrow Transplant, Vancouver General Hospital, Canada
• Sep 2017-Jan 2022: Consultant Hemato-Oncologist and BMT Physician, Manipal Hospitals, Vijayawada, Andhra Pradesh
• June 2013-Nov 2013: Resident Doctor, Department of Medical Oncology, HCG Cancer Center, Bengaluru

Services offered

• Chemotherapy
• Immunotherapy
• Autologous and Allogeneic Stem Cell Transplant
• Targeted Therapy
• Supportive and Palliative Care
• Cancer Nutrition
• Cancer Survivorship

Special Interest and Expertise

• Blood Cancers (Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Multiple Myeloma, Lymphoma)
• Myelodysplastic Syndrome (MDS), Myeloproliferative Neoplasm (MPN)
• Blood Disorders (Anemia, Thalassemia, Sickle Cell Anemia)
• Autologous and Allogeneic Stem Cell Transplants (Matched Sibling Donor, Matched/Mismatched Unrelated Donor, Haploidentical Donor, Cord Blood Transplants)
• Childhood Cancers
• Cellular Therapy (CAR-T Cells)

Professional Membership

• Medical Oncology Forum (MOF)
• Collaborative Medical Oncology Group (CMOG)

Research & Publications

• Danthala M, Kallur KG, Prashant GR, Rajkumar K, Rao MR. 177 Lu-DOTATATE therapy in patients with neuroendocrine tumours: 5 years experience from a tertiary cancer care centre in India. European Journal of Nuclear Medicine and Molecular Imaging. 2014 Jul;41(7):1319-26.
• Danthala M, Gundeti S, Kuruva SP, Puligundla KC, Adusumilli P, Karnam AP, Bala S, Konatam ML, Maddali LS, Digumarti RR. Generic imatinib in chronic myeloid leukemia: survival of the cheapest. Clinical Lymphoma Myeloma and Leukemia. 2017 Jul 1;17(7):457-62.
• Danthala M, Golamari KR, Seshachalam A, Mikkilineni A, Chappidi S, Mekala MB, Elangovan V, Chinnakali P. Walking a Tightrope: Dosage Modifications and Treatment Outcomes of All Trans-Retinoic Acid, Arsenic Trioxide, and Daunorubicin for HighRisk Acute Promyelocytic Leukemia. JCO Global Oncology. 2020 Nov;6:1749-56.
• Danthala M, Gundeti S, Maddali LS, Pillai A, Puligundla KC, Adusumilli RP. Philadelphia chromosome-positive acute lymphoblastic leukaemia: 8 years experience from a tertiary care center in India. South Asian Journal of Cancer. 2016 Oct;5(04):176-8.
• Karpurmath SV, Seshachalam A, Selvaraj K, Rajamani P, Reddy N, Malipatil B, Sirigeri R, Prasad K, Reddy K, Danthala M, Udupa KS. Halving Time of BCR-ABL1 in Chronic Myeloid Leukemia: Is It Better Than Day-90 Value—A Multicenter Study from South India. Clinical Lymphoma Myeloma and Leukemia. 2020 May 1;20(5):e205-11.
• Seshachalam A, Karpurmath SV, Rathnam K, Raman SG, Janarthinakani M, Prasad K, Patil C, Anoop P, Reddy N, Anumula SK, Roopa SP, Danthala M. Does Interim PET Scan After 2 Cycles of ABVD Predict Outcome in Hodgkin Lymphoma? Real-World Evidence. Journal of Global Oncology. 2019 Dec;5:1-3.
• Adusumilli P, Gundeti S, Danthala M, Pk C. 301P Long term survival and late side effects of paediatric Hodgkin lymphoma patients: a study from a tertiary care centre in Southern India. Annals of Oncology. 2015 Dec 1;26(suppl_9):ix89. 
• Puligundla CK, Gundeti S, Bala S, Pillai A, Adusumilli P, Danthala M, Konatam ML, Maddali LS. Mutation Analysis and Treatment Outcomes of BCR-ABL Tyrosine Kinase Domain in CML Patients with Imatinib Treatment Failure-Data from a Large Tertiary Center in India. Blood 2016 vol: 128 (22) pp: 1910-1910.
• Danthala M, Rajesh GR, Gundeti S, Raju GS, Chandran P, Srinivas ML. Obesity and Breast Cancer: Association of serum adiponectin, leptin, and adiponectin–leptin ratio as risk biomarkers. Indian Journal of Medical and Paediatric Oncology. 2018 Jul;39(03):292-6.
• Danthala M, Lakshmaiah V. Correlative study of serum cystatin C levels with severity of acute ischemic stroke. J Clin Biomed Sci. 2013;3(4):188-92.
• Naveen L, Santoshi M, Madhav D, Sri Rama AG, Mahesh V. A study of the association of insulin resistance and cardiometabolic risk factors in an adult population with type 2 diabetes mellitus, Inter. J. Appl. Med. Sci. 2014;4:168-72.

Posters/papers/oral Presentations

• Proffered Paper: Additional chromosomal abnormalities in chronic myeloid leukemia: lest we forget. Presented at ESMO (European Society of Medical Oncology) Asia 2016, Singapore
• Generic Imatinib in Chronic Myeloid Leukemia: Survival of the Cheapest. Presented at ASH 2016 (Annual American Society of Hematology Conference), San Diego. Shortlisted for Best of ASH
• Microalbuminuric anemia: A study of the relationship between hemoglobin levels and albuminuria in diabetes. KAPICON 2012
• Obesity and breast cancer: Association of serum adiponectin, leptin and adiponectin-leptin ratio as risk biomarkers. Presented  at Annual Indian Society of Medical and Pediatric Oncology Conference, 2016 at Delhi
• Renal Reversibility in Multiple Myeloma: A race against the clock! Presented at Myeloma: State of the Art, 2016, PGI Chandigarh
• Philadelphia chromosome-positive acute lymphoblastic leukemia: 8 years’ experience from a tertiary care center in India. Presented at Annual Asian Clinical Oncology Society Conference 2016, Delhi
• Validation of an enhanced International Prognostic Index (NCCN IPI) in patients with diffuse large B cell lymphoma in the Rituximab era: 7 years’ experience from a tertiary care center in  South India. Presented at ICON 2016, received the Best Poster Presentation Award
• Frontline Imatinib in Chronic Myeloid Leukemia: A Jewel in the Crown, Presented at Hematocon 2016, Jaipur
• Pediatric chronic myeloid leukemia: wise to generalize? Presented at ISMPOCON 2016, Delhi
• Monosomy 7 and Deletion 7q in Acute Myeloid Leukemia – M0/ M1 with prior Myelodysplastic syndrome transformed from Fanconi Anemia – a case report. HEMATOCON 2015
• Phenytoin induced Cerebellar Ataxia and Orofacial Dyskinesia in  a rare case of Disseminated Cysticercosis. APICON 2013

Awards and Achievements

• Instrumental in successfully setting up the Allogeneic Stem Cell Transplant Program at Manipal Hospitals, Vijayawada and performed more than 50 Stem Cell Transplants, the highest in the state.
• Performed the First Matched Sibling Donor and Haploidentical Stem Cell Transplant in Andhra Pradesh
• University Topper (SDUAHER) Internal Medicine (2013)
• 1st Rank, DM Medical Oncology Entrance Examination, Nizam’s Institute of Medical Sciences

  FAQ'S

1. 1. Why do patients frequently visit Dr. Madhav Danthala?
   

   Patients visit Dr. Madhav Danthala to receive treatment for various blood cancers and blood-related disorders.

2. 2. What is Dr. Madhav Danthala's educational qualification?
   

   Dr. Madhav Danthala holds the following qualifications: MD, DM (Medical Oncology, NIMS), Fellowship in Leukemia and Bone Marrow Transplantation (Canada).

3. 3. What does Dr. Madhav Danthala specialise in?
   

   Dr. Madhav Danthala is a Consultant Hemato-Oncologist and Bone Marrow Transplant Physician who specialises in Blood Cancers, Blood Disorders, Autologous and Allogeneic Stem Cell Transplants, and Cellular Therapy (CAR-T Cells), among others.

4. 4. Where does Dr. Madhav Danthala practice?
   

   Dr. Madhav Danthala practices at Yashoda Hospitals, Somajiguda.

5. 5. How can I book Dr. Madhav Danthala’s appointment?
   

   You can schedule an appointment with Dr. Madhav Danthala for both an Online Video Consultation and an OPD Consultation by visiting his profile on Yashoda Hospitals.